A5013149000- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Research and Treatments
- Cancer-related gene regulation
- Monoclonal and Polyclonal Antibodies Research
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- CAR-T cell therapy research
- Biosimilars and Bioanalytical Methods
- Peptidase Inhibition and Analysis
- Colorectal and Anal Carcinomas
- Lung Cancer Research Studies
- Barrier Structure and Function Studies
- Congenital Diaphragmatic Hernia Studies
- TGF-β signaling in diseases
- Helicobacter pylori-related gastroenterology studies
- Advanced Breast Cancer Therapies
- Pediatric Pain Management Techniques
- Immunotherapy and Immune Responses
Henan Cancer Hospital
2019-2025
Zhengzhou University
2013-2025
Ligand Pharmaceuticals (United States)
2024
BitPlus (United States)
2024
Next Generation Technology (United States)
2024
Check Point (Israel)
2024
Feminist Archive South
2024
Shanghai Micro Satellite Engineering Center
2024
Computer Emergency Response Team
2024
General Electric (Norway)
2024
Importance Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, few effective treatments available. Sintilimab, a recombinant human IgG4 monoclonal antibody that binds to programmed cell death (PD-1), combination with chemotherapy, has demonstrated promising efficacy. Objective To compare overall survival of patients unresectable locally advanced or metastatic gastric who were treated sintilimab chemotherapy vs placebo chemotherapy....
Background: The addition of immune checkpoint inhibitors to neoadjuvant chemotherapy in operable advanced gastric or gastroesophageal junction (G/GEJ) cancer aroused wide interest. This study was designed assess the efficacy and safety sintilimab, a programmed cell death protein-1 (PD-1) inhibitor, combination with fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT) for HER2-negative locally G/GEJ cancer. Methods: Eligible patients clinical stage cT4 and/or cN+M0 were enroled this phase...
406 Background: The evidence of conversion therapy for unresectable GC/GEJC is limited. Previously, preliminary results the ongoing open-label, phase 2 study (NCT05177068) have showed promising R0 surgical rate (62.1%), resection (100%) and acceptable tolerability in with sintilimab fruquintinib plus SOX (ASCO 2024). Here we present updated longer follow-up duration, including more enrolled patients. Methods: Eligible patients were administered (4mg/d, po, qd, d1-14), (200mg, iv, d1),...
190 Background: Panitumumab plus FOLFOX or FOLFIRI has been approved as the first-line therapy for RAS wild-type mCRC. QL1203 is a panitumumab biosimilar showing similarity to originator (Vectibix, Amgen) in preclinical studies and phase 1 clinical pharmacokinetic study. Here we present results from interim analysis of 3 trial (NCT04233151) investigating vs placebo mFOLFOX6 Chinese patients (pts) with Methods: Pts treatment-naïve, BRAF wild-type, mCRC unsuitable radical resection local were...
Abstract Background: The phase III ORIENT-16 trial evaluated sin (a PD-1 inhibitor) versus placebo plus chemo as first-line (1L) treatment in pts with advanced G/GEJ adenocarcinoma. Sin+chemo previously showed a significant improvement OS vs PD-L1 combined positive score (CPS) ≥5 (HR 0.660; 95% CI 0.505-0.864; P=0.0023) and all 0.766; 0.626-0.936; P=0.0090), median follow-up of 18.8 months (m) at interim analysis (Xu, et al. Ann Oncol 2021). Here we report the results from final...
434420 Background: Claudin 18.2 (CLDN18.2) is a promising therapeutic target for advanced gastric/gastroesophageal junction (G/GEJ) cancer. CMG901, potential first-in-class CLDN18.2-targeted antibody-drug conjugate carrying monomethyl auristatin E (MMAE), has demonstrated potent anti-tumor activity in preclinical studies. Methods: This phase 1 trial included dose-escalation (part A; 0.3-3.4 mg/kg) and dose-expansion B; 2.2, 2.6, 3.0 to evaluate safety, tolerability, of CMG901 patients (pts)...
HLX04 is a proposed biosimilar of bevacizumab. This phase III study aimed to evaluate the efficacy, safety, and immunogenicity compared with reference bevacizumab in combination XELOX or mFOLFOX6 as first-line treatment for recurrent/metastatic colorectal cancer (CRC). In this double-blind, parallel-group study, patients were randomized 1:1 receive (7.5 mg/kg every 3 weeks when combined XELOX; 5 2 mFOLFOX6). The primary endpoint was progression-free survival rate at week 36 (PFSR36w) per...
To evaluate pembrolizumab in patients of Chinese descent with microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) tumors enrolled KEYNOTE-158 (Cohort L).
391 Background: Claudin18.2 (CLDN18.2) is normally confined in tight junction of the gastric mucosa, but also often expressed several cancer types. AB011 a humanized, anti-CLDN18.2 monoclonal antibody (IgG1), which has shown impressive therapeutic synergy between and cytotoxic agents preclinical research. Here we report preliminary data on both as monotherapy combined with CAPOX patients advanced solid tumors (AB011-ST-01, NCT04400383). Methods: The primary objectives were to evaluate safety...
<h2>Summary</h2><h3>Background</h3> Limited therapeutic options are available for metastatic colorectal cancer (mCRC) patients after failure of first- and second-line therapies, representing an unmet medical need novel therapies. <h3>Methods</h3> This is open-label, single arm, multicenter, phase Ⅱ study aiming to perform the efficacy, safety genomic analysis SCT200, a noval fully humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in with fluorouracil,...
2512 Background: PM8001 is a bifunctional protein composed of the extracellular domain TGF-β RII receptor (a “trap”) fused to humanized anti-PD-L1 IgG1 single-domain antibody. This first dose escalation and expansion phase I/IIa study evaluate safety preliminary anti-tumor activity in advanced tumors. Methods: comprised standard 3+3 (Part A: 1, 3, 10, 20, 30, 45 mg/kg Q2W) followed by B). Primary endpoints include for Part A, ORR per RECIST 1.1 B. Secondary pharmacokinetics (PK),...
3582 Background: Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in hematologic malignancies but limited success solid tumors. GCC19CART, the first candidate from CoupledCAR tumor platform, is designed to overcome limitations of conventional CAR T-cells by pairing with CD19 targeting amplify proliferation and activation T component. GCC19CART targets guanylate cyclase-C (GCC) which expressed metastatic lesions 70%-80% subjects colorectal cancers. A Phase...
Abstract Background PAX8 was not only a mitotic factor, but identified as transcription factor involved in the prognosis of human tumor patients. Elucidating function on pathology stomach cancer meaningful. Results found to be upregulated primary tissue and TCGA dataset. Interestingly, SOX13 showed consistent expression patterns, combined high SOX18 induced worse further PAX8, affect Aurora B Cyclin B1 expression, two cell cycle related factors downstream including. Furthermore, depletion...
3000 Background: Folate receptor α (FRα) and vanilloid subfamily member 6 of transient potential channels (TRPV6) are overexpressed in many solid tumors hence could be promising therapeutic targets. CBP-1008 is a first-in-class bi-specific ligand drug targeting FRα TRPV6 carrying monomethyl auristatin E (MMAE) as payload. Here we report the first-in-human, multicenter, phase Ia/Ib study designed to explore safety, pharmacokinetics efficacy advanced tumors. Methods: was administered by...
<title>Abstract</title> <bold>Background</bold>Breakthrough cancer pain (BTcP) has a negative impact on patients’ quality of life, general activities, and is related to worse clinical outcomes. Fentanyl inhalant hand-held combination drug-device delivery system providing rapid, multi-dose (25μg/dose) administration fentanyl via inhalation thermally generated aerosol. This multicenter, randomized, placebo-controlled, multiple-crossover, double-blind study evaluated the efficacy, safety,...
2592 Background: LBL-015 is a bispecific fusion protein which consists of fully anti PD-1 monoclonal antibody and TGF-βRII ectodomain, designed to block PD-1/PD-L1 TGFβ signal pathway, reversing immune suppression promoting anti-tumor immunity. Here we report the preliminary safety efficacy in patients with advanced solid tumors. Methods: This phase Ⅰ, open-label, multicenter, dose-escalation study evaluate safety, tolerability, PK tumors that progressed after standard therapy. The dose...
e16021 Background: The evidence of conversion therapy for unresectable GC/GEJC is limited. Fruquintinib an oral, highly selective VEGFR 1/2/3 inhibitor that has synergistic antitumor effects when combined with ICIs/chemotherapy. This study was conducted to evaluate the efficacy and safety fruquintinib sintilimab SOX as a in patients (pts) initially locally advanced or metastatic GC/GEJC. Methods: Eligible pts received 3 6 cycles (4mg/d, po, qd, d1-14) (200mg, iv, d1), oxaliplatin (130 mg/m 2...
e16011 Background: PD-1 inhibitor combined with chemotherapy are the standard first-line treatment for advanced ESCC. Anlotinib, a multitargeted tyrosine kinase (TKI), has been demonstrated favorable efficacy and manageable toxicity as both when TP second-line monotherapy in TQB2450 is novel humanized anti-PD-L1 monoclonal antibody. We conducted phase II trial to evaluate safety of alotinib TQB2450, cisplatin, paclitaxel Here update results. Methods: Eligible patients (pts) previously...
Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in hematologic malignancies but limited success solid tumors. GCC19CART, the first candidate from CoupledCAR tumor platform, is designed to overcome limitations of conventional CAR T-cells by pairing with CD19 targeting amplify proliferation and activation T component. GCC19CART targets guanylate cyclase-C (GCC) which expressed metastatic lesions 70%-80% subjects colorectal cancers. A...
4040 Background: Outcomes of second or later-line treatment for pts with advanced GC/GEJC remain inferior. KN026 is a novel HER2-targeted bispecific antibody composed VH regions trastuzumab and pertuzumab, targeting the HER2 juxtamembrane domain (IV) dimerization (II) simultaneously. has shown promising antitumor efficacy in preclinical phase I studies. Here we present results monotherapy previously treated, HER2-expressing GC/GEJC. Methods: In this multi-center, single-arm, open-label,...
<title>Abstract</title> PAX8 is identified as a regulator in the pathogenesis of human tumors and an indicator prognosis for patients. However, role on proliferation gastric cancer have not been studied. This study was aimed to explore expression pattern cancer, investigate effect cells. SOX13 were be synchronously upregulated primary tissues datasets TCGA, patients combined high showed poor prognosis. Furthermore, can mediate its targeted genes, Aurora B Cyclin B1, AGS MGC803 cell lines....